A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction

BACKGROUND. The phase II YO28252 study (NCT01590719) examined first-line onartuzumab plus mFOLFOX6 in patients with metastatic, human epidermal growth factor receptor 2-negative adenocarcinoma of the stomach or gastroesophageal junction. MET immunohistochemistry expression as a biomarker of onartuzu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Shah, Manish A., Cho, Jae-Yong, Tan, Iain B., Tebbutt, Niall C., Yen, Chia-Jui, Kang, Alice, Shames, David S., Bu, Lilian, Kang, Yoon-Koo
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2016
Matèries:
Gastrointestinal Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5016069/
https://ncbi.nlm.nih.gov/pubmed/27401892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0038
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars